TFTaiki Furukawa

Taiki Furukawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taiki Furukawa has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Kensuke Kataoka

    Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan

    16 shared publications
  • Yoshinori Hasegawa

    NHO Nagoya Medical Center, Nagoya, Japan

    13 shared publications
  • Yasuhiro Kondoh

    Department of Respiratory Medicine and Allergology, Aichi Medical University, 1-1 Yazako Karimata, Nagakute, Aichi, 480-1195, Japan; Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160, Nishi-oiwake-cho, Seto, Aichi, 489-8642, Japan

    11 shared publications
  • Takeshi Johkoh

    Department of Radiology, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan

    10 shared publications
  • Tomoki Kimura

    Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan

    10 shared publications
  • Yasuhiro Kondoh

    Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan

    10 shared publications

Latest Publications

  • Open Access

    Effectiveness of and implementation requirements for telehealth in palliative care patients with advanced cancer: A systematic review and meta-analysis

    by Arisa Kawashima, Taiji Noguchi, Taiki Furukawa, Akiko Unesoko, Shintaro Togashi, Kazuki Sato

    Background: Telehealth is being integrated with palliative care for patients with advanced cancer to improve access to specialized palliative care. However, its effectiveness and implementation requirements in palliative care remain unclear. Aim: This study evaluates the effectiveness of and implementation requirements for telehealth in palliative care patients with advanced cancer. Design: This was designed as a systematic review and meta-analysis with narrative synthesis (registered; CRD42024581786). The effects on patients’ quality of life, symptom burden, and depression were analyzed using a random-effects meta-analysis of randomized controlled trials. A narrative synthesis was conducted for all included studies. Data sources: MEDLINE, Embase, and Cochrane Library databases were searched in September 2025. Eligible studies comprised controlled trials, observational studies, and qualitative studies involving adults with advanced cancer who received telehealth in palliative care. Results: Of the 4232 records screened, 42 met the inclusion criteria, and six were eligible for meta-analysis. Telehealth interventions primarily involved videoconferencing, telephone, or text-based communication. Telehealth in palliative care demonstrated significant improvement in quality of life (standardized mean difference: 0.81; 95% CI: 0.09-1.53) and reduction in symptom burden (standardized mean difference: −1.44; 95% CI: −2.24 to −0.65) but had no significant effects on depression. Implementation requirements included trained multiprofessional teams, accessible digital infrastructure, sustainable reimbursement mechanisms, and standardized outcome measurements. Conclusions: Telehealth in palliative care may help improve quality of life and alleviate symptom burden among patients with advanced cancer. Future research should identify optimal delivery models and examine equity-related barriers to support wider implementation and policy development.


  • Desaturation in the six-minute walk test predicts progressive pulmonary fibrosis in fibrotic interstitial lung disease

    by Reoto Takei, Jun Fukihara, Yasuhiko Yamano, Kensuke Kataoka, Tomoki Kimura, Fumiko Watanabe, Taiki Furukawa, Junya Fukuoka, Takeshi Johkoh, Yasuhiro Kondoh


  • Deep Learning for Predicting Acute Exacerbation and Mortality of Interstitial Lung Disease

    by Ryo Teramachi, Taiki Furukawa, Yasuhiro Kondoh, Masayuki Karasuyama, Hironao Hozumi, Kensuke Kataoka, Shintaro Oyama, Takafumi Suda, Yoshimune Shiratori, Makoto Ishii

    Rationale: Some patients with interstitial lung disease (ILD) have a high mortality rate or experience acute exacerbation of ILD (AE-ILD) that results in increased mortality. Early identification of these high-risk patients and accurate prediction of the onset of these important events is important to determine treatment strategies. Although various factors that affect disease behavior among patients with ILD hinder the accurate prediction of these events, the use of longitudinal information may enable better prediction. Objectives: To develop a deep learning (DL) model to predict composite outcomes defined as the first occurrence of AE-ILD and mortality using longitudinal data. Methods: Longitudinal clinical and environmental data were retrospectively collected from consecutive patients with ILD at two specialty centers between January 2008 and December 2015. A DL model was developed to predict composite outcomes using longitudinal data from 80% of patients from the first center, which was then validated using data from the remaining 20% of patients and the second center. The developed model was compared with the univariate Cox proportional hazard (CPH) model using the ILD gender-age-physiology (ILD-GAP) score and multivariate CPH model at the time of ILD diagnosis. Results: AE-ILD was reported in 218 patients among the 1,175 patients enrolled, whereas 380 died without developing AE-ILD. The truncated concordance index (C-index) values of univariate/multivariate CPH models for composite outcomes within 12, 24, and 36 months after prediction were 0.789/0.843, 0.788/0.853, and 0.787/0.853 in internal validation, and 0.650/0.718, 0.652/0.756, and 0.640/0.756 in external validation, respectively. At 12 months after ILD diagnosis, the DL model outperformed the univariate CPH model and multivariate CPH model for composite outcomes within 12 months, with concordance index values of 0.842, 0.840, and 0.839 in internal validation, and 0.803, 0.744, and 0.746 in external validation, respectively. Neutrophils, C-reactive protein, ILD-GAP score, and exposure to suspended particulate matter were strongly associated with the composite outcomes. Conclusions: The DL model can accurately predict the incidence of AE-ILD or mortality using longitudinal data.


  • Development and Evaluation of a Comprehensive Machine Learning Tool Differentiating Idiopathic Pulmonary Fibrosis from Other Interstitial Lung Diseases in the Japanese nationwide registry (PROMISE study).

    by Taiki Furukawa, Yasuhiro Kondoh, Shintaro Oyama, Hideo Yokota, Ryo Teramachi, Hironao Hozumi, Yoshimune Shiratori, Yoshinori Hasegawa, Takafumi Suda, Makoto Ishii, et al.

    Background and Objective: Idiopathic Pulmonary Fibrosis (IPF) is characterized by a poor prognosis and a low rate of diagnostic consensus. Then, we have developed a comprehensive machine learning tool to differentiate IPF from other Interstitial Lung Diseases (ILDs) using non-invasive tests typically employed in ILD assessment. This study aimed to refine and evaluate the algorithm with the PROMISE study, a prospective, nationwide registry in Japan. Methods: From September 2020 to October 2022, newly diagnosed ILD cases from 133 respiratory hospitals across Japan were registered and reviewed by an online central Multidisciplinary Discussion (MDD). Our previously reported model (Furukawa et al. Respirology 2022;27:739-746.) was re-trained with MDD diagnoses from 97 institutions and evaluated on the remaining 36 institutions. Results: The study included 2,751 patients, average age 69.1 years, 63.5% male, with 652 diagnosed with IPF by MDD. Cases for interim analysis were randomly divided into training and testing datasets based on facility, with 1,782 and 655 cases. The algorithm previously reported an accuracy of 83.6% at a single institution, achieved 83.4% accuracy in this nationwide registry for MDD-IPF. Conclusion: Using non-invasive data, this comprehensive machine learning tool to differentially diagnose IPF from other ILDs showed efficient, accurate, and rapid diagnosis. This approach provides a notable advancement in the diagnostic process of ILDs, and a reliable alternative to traditional diagnostic methods.


  • Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease

    by Tomonori Sato, Taiki Furukawa, Ryo Teramachi, Jun Fukihara, Yasuhiko Yamano, Toshiki Yokoyama, Toshiaki Matsuda, Kensuke Kataoka, Tomoki Kimura, Koji Sakamoto, et al.

    Background Pulmonary hypertension (PH) is defined by elevated mean pulmonary arterial pressure (MPAP), and elevated pulmonary vascular resistance (PVR) reflects pulmonary vascular abnormalities. The clinical significance of non-severe PH in patients with various interstitial lung diseases (ILDs) has not been fully elucidated. We aimed to investigate the clinical significance of MPAP and PVR for mortality in patients with newly diagnosed ILD. Methods We retrospectively analysed consecutive patients with ILD at initial evaluations that included right heart catheterisation from 2007 to 2018. These patients were classified by MPAP and PVR using the 2022 the European Society of Cardiology (ESC)/the European Respiratory Society (ERS) guidelines for PH. The clinical significance of MPAP and PVR for mortality was analysed. Results Among 854 patients, 167 (19.6%) had MPAP>20 mm Hg. The proportion of patients with PVR>2 Wood units (WU) among those with MPAP≤20 mm Hg, 20Conclusions Mild elevation of PVR was associated with a higher mortality rate in patients with newly diagnosed ILD, even in those with MPAP≤20 mm Hg.


  • Nationwide All ILD registry with central MDD in Japan; Providing Multidisciplinary ILD diagnoses (PROMISE) study.

    by Taiki Furukawa, Yasuhiro Kondoh, Shintaro Oyama, Ryo Teramachi, Hironao Hozumi, Takafumi Suda, Tomoyuki Fujisawa, Ryoko Egashira, Takeshi Johkoh, Junya Fukuoka, et al.

    Background: Multidisciplinary discussion (MDD) is the gold standard for diagnosis of interstitial lung disease (ILD). However, in cases with 50% or less diagnostic confidence or possible new entities (smoking-related ILD; SR-ILD and NSIP with OP), a diagnosis of unclassifiable ILD (UC-ILD) is made. Moreover, the impact of the ATS/JRS/ALAT guideline for hypersensitivity pneumonitis (HP) on the overall ILD diagnosis is unclear. Objective: To investigate disease frequencies of ILD including new entities in an interim analysis result. Method: This prospective nation-wide registry (PROMISE study) enrolled cases from 133 referral respiratory hospitals in Japan from September 2020 to October 2022, for which central MDDs were conducted through an online MDD platform. This study provides 3-year follow-up. Results: This study included 2,741 patients with a mean age of 69.1 years, of whom 63.7% were male, 9.2% surgical lung biopsy, and 24.0% cryobiopsy. Based on MDD made within a mean of 8 days, frequencies of idiopathic pulmonary fibrosis, UC-ILD, HP, and connective tissue disease related ILD were 23.8%, 24.9%, 22.2%, and 13.8%, respectively. Non-IPF fulfilled progressive fibrosing ILD was seen in 13.7% of cases by enrollment. The reason for diagnosis of UC-ILD was diagnostic confidence of 30 to 50% in 29%, NSIP with OP in 18 %, and SR-ILD in 17%. MDD resulted in a change in 47% of institutional diagnoses, and in 83% of institutional UC-ILD. 33% of MDD-IPF and 57% of MDD-HP showed discordant institutional diagnosis. Conclusion: This registry revealed the relative distribution of specific ILD, the details of UC-ILD, and the differences between central MDD and institutional diagnosis.


  • DEVELOPMENT OF A MACHINE-LEARNING MODEL FOR PREDICTING POST-ERCP PANCREATITIS

    by Takahashi Hidekazu, Eizaburo Ohno, Taiki Furukawa, Kentaro Yamao, Takuya Ishikawa, Yasuyuki Mizutani, Tadashi Iida, Yoshimune Shiratori, Shintaro Oyama, Junji Koyama, et al.

  • Open Access

    Prognostic Factors for Covid-19 on Admission Profile and Air Pollutants

    by Kikue Sato, Taiki Furukawa, Satoshi Yamashita, Daisuke Kobayashi, Shintaro Oyama, Yoshimune Shiratori

    It has been reported that the severity and lethality of Covid-19 are associated with coexisting underlying diseases (hypertension, diabetes, etc.) and cardiovascular diseases (coronary artery disease, atrial fibrillation, heart failure, etc.) that increase with age, but environmental exposure such as air pollutants may also be a risk factor for mortality. In this study, we investigated patient characteristics at admission and prognostic factors of air pollutants in Covid-19 patients using a machine learning (random forest) prediction model. Age, Photochemical oxidant concentration one month prior to admission, and level of care required were shown to be highly important for the characteristics, while the cumulative concentrations of air pollutants SPM, NO2, and PM2.5 one year prior to admission were the most important characteristics for patients aged 65 years and older, suggesting the influence of long-term exposure.

  • A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases

    by Taiki Furukawa, Shintaro Oyama, Hideo Yokota, Yasuhiro Kondoh, Kensuke Kataoka, Takeshi Johkoh, Junya Fukuoka, Naozumi Hashimoto, Koji Sakamoto, Yoshimune Shiratori, et al.

    Background and objective: Idiopathic pulmonary fibrosis (IPF) has poor prognosis, and the multidisciplinary diagnostic agreement is low. Moreover, surgical lung biopsies pose comorbidity risks. Therefore, using data from non‐invasive tests usually employed to assess interstitial lung diseases (ILDs), we aimed to develop an automated algorithm combining deep learning and machine learning that would be capable of detecting and differentiating IPF from other ILDs.Methods: We retrospectively analysed consecutive patients presenting with ILD between April 2007 and July 2017. Deep learning was used for semantic image segmentation of HRCT based on the corresponding labelled images. A diagnostic algorithm was then trained using the semantic results and non‐invasive findings. Diagnostic accuracy was assessed using five‐fold cross‐validation.Results: In total, 646,800 HRCT images and the corresponding labelled images were acquired from 1068 patients with ILD, of whom 42.7% had IPF. The average segmentation accuracy was 96.1%. The machine learning algorithm had an average diagnostic accuracy of 83.6%, with high sensitivity, specificity and kappa coefficient values (80.7%, 85.8% and 0.665, respectively). Using Cox hazard analysis, IPF diagnosed using this algorithm was a significant prognostic factor (hazard ratio, 2.593; 95% CI, 2.069–3.250; p < 0.001). Diagnostic accuracy was good even in patients with usual interstitial pneumonia patterns on HRCT and those with surgical lung biopsies.Conclusion: Using data from non‐invasive examinations, the combined deep learning and machine learning algorithm accurately, easily and quickly diagnosed IPF in a population with various ILDs.


  • Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype

    by Reoto Takei, Kevin K. Brown, Yasuhiko Yamano, Kensuke Kataoka, Toshiki Yokoyama, Toshiaki Matsuda, Tomoki Kimura, Atsushi Suzuki, Taiki Furukawa, Junya Fukuoka, et al.

    Background and objective: The development of clinically progressive fibrosis complicates a wide array of interstitial lung diseases (ILDs). However, there are limited data regarding its prevalence and prognosis.Methods: We analysed consecutive patients seen for initial evaluation of a fibrosing form of ILD (FILD). Patients were evaluated for evidence of progressive fibrosis over the first 24 months of follow‐up. We defined a progressive phenotype as the presence of at least one of the following: a relative decline in forced vital capacity (FVC) of ≥10%; a relative decline in FVC of ≥5%–p p p p = 0.42).Conclusion: Over one‐fourth of non‐IPF FILD patients develop a progressive phenotype compared to approximately 60% of IPF patients. The survival of non‐IPF FILD patients with a progressive phenotype is similar to IPF.